Skip to main content
. 2023 Jul 6;14:1182304. doi: 10.3389/fneur.2023.1182304

Table 5.

The effects of PER on various sleep parameters (184).

Study Risk of bias Main population (adult/adol/peds) Comparator SE TST SL WASO Arousals/awake N1 N2 N3 REM PSQI ESS/SSS Insomnia
González-Cuevas et al. (190) High Focal epilepsy (adult; >16 years) Baseline NA NA NA NA NA NA −/NA NA
Lee et al. (192) Moderate Epilepsy (adult) Drug-naïve NA NA NA NA NA NA NA NA NA NA −/NA
Rocamora et al. (193) Moderate Refractory epilepsy (adult) Baseline −/NA NA
Romigi et al. (191) High Focal epilepsy (adult) Baseline NA NA NA NA NA NA NA NA NA −/NA NA
Toledo et al. (189) Moderate Refractory focal epilepsy (adult; >16 years) Baseline NA NA NA NA NA NA NA NA NA ↓ (3 months)/NA; − (6 months)/NA − (3 months)/NA; ↓ (6 months)/NA NA

Reproduced and adapted from Elsevier Ltd. under the terms of a Creative Commons license (CC BY-NC-ND 4.0). Adol, adolescent; ASM, anti-seizure medication; CAE, childhood absence epilepsy; EDS, excessive daytime sleepiness; ESS, Epworth Sleepiness Scale; HV, healthy volunteer; JME, juvenile myoclonic epilepsy; N1, stage N1; N2, stage N2; N3, stage N3; peds, pediatric; PBO, placebo; PSQI, Pittsburgh Sleep Quality Index; REM, rapid eye movement; SE, sleep efficiency; SL, sleep latency; SSS, Stanford Sleepiness Scale; TLE, temporal lobe epilepsy; TST, total sleep time; WASO, Wake After Sleep Onset; AND NA, not available.

↓, decrease; ↑, increase; −, no change.

In a stepwise logistic regression model, clinically diagnosed insomnia was negatively associated with perampanel use in the study by Lee et al. (192).